Clinical Trials Directory

Trials / Completed

CompletedNCT01345760

Expression Levels of RISC and Microprocessor Complex Components in Epithelial Skin Cancer

Expression Levels of RNA-induced Silencing Complex (RISC) Components TARBP1, TARBP2, Argonaute-1, Argonaute-2, PACT and Microprocessor Complex Component DGCR8 in Epithelial Skin Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
44 (actual)
Sponsor
Ruhr University of Bochum · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study, the investigators examines the expression profiles of the microprocessor complex subunit DGCR8 and the RISC components TARBP1, TARBP2, argonaute-1, argonaute-2 and PACT in epithelial skin cancer and its premalignant stage.

Detailed description

Patients with premalignant actinic keratoses, basal cell carcinomas and squamous cell carcinomas were included in the study. Punch biopsies were harvested from the center of the tumors, from sites of healthy skin and a healthy control group. DGCR8, TARBP1, TARBP2, argonaute-1, argonaute-2 and PACT mRNA expression levels were detected by quantitative real-time reverse transcriptase polymerase chain reaction.

Conditions

Timeline

Start date
2008-07-01
Primary completion
2011-02-01
Completion
2011-02-01
First posted
2011-05-02
Last updated
2012-10-16

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01345760. Inclusion in this directory is not an endorsement.